ArticleJournal of global health2025
Impact of pooled procurement of medicines on patient adherence and economic burden: evidence from China.
Article in Journal of global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Plan-related inequalities in costs, disease progression and mortality among hypertensive patients in China.Nature communications · 2026Article
- Governance absorption of volume-based procurement: study of dual-track implementation in a public hospital.Frontiers in public health · 2026Article
- Impact of the national centralized volume-based procurement policy on antihypertensive drug procurement, price, and volume in Guangxi: an interrupted time series analysis of procurement data.Frontiers in pharmacology · 2026Article
- Medication Discrepancy in the Hospital-to-Home Transition Period of Elderly Chinese Patients with Coronary Heart Disease: A Qualitative Study.Patient preference and adherence · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pooled procurement is widely adopted to improve medicine affordability, yet its impact on patients' medicine adherence and economic burden remains underexplored. This study addresses these gaps under China's National Volume-Based Procurement (NVBP) policy. Methods: Using claims data from Tianjin, China (2017-2020), we conducted a retrospective cohort study of new-users of NVBP antihypertensive medicines before and after policy implementation. During one-year follow-up since medicine initiation, medicine adherence (measured by proportional days covered), medicine persistence (measured by discontinuation rate), and direct medical costs (broken down by components) were compared between cohorts. Linear regressions, Cox proportional hazard models and generalised linear models were used to analyse outcome differences, adjusting for patients' demographics, medical history, and prior health care utilisation. Results: We identified 14 560 and 18 858 patients in pre- and post-policy cohorts, respectively (mean age = 57.1; 52.8% men). Compared to the pre-policy cohort, the post-policy cohort presented a slight increase in adherence to NVBP medicines (proportional days cover = 0.31 vs. 0.28; adjusted difference = 0.021; P < 0.0001), but no significant change in discontinuation rate. Hypertension-related costs decreased by 19.5% (1509.2 vs. 1804.8 Chinese Yuan; P < 0.0001) for the post-policy cohort, entirely attributed to saving in costs of NVBP medicines (480.6 vs. 772.6 Chinese Yuan; adjusted difference = -47.5%; P < 0.0001). No significant difference was observed in costs for other medicines and services. The cost saving was equally borne by patients and health plans. Conclusions: China's NVBP modestly improved adherence and significantly reduced the economic burden for patients. To fully deliver patient-centred benefits of pooled procurement for chronic disease medicines beyond price cuts, it should be paired with supply- and demand-side auxiliary measures. China's experience, including financial incentives, regulatory oversight, favourable reimbursement policies and public campaigns, may offer lessons for other settings. Longer-term studies in broader populations are needed to further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.